Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 16,149	$ 59,640
Short-term investments	249,398	329,462
Accounts receivable, net	4,114	15,678
Inventory	11,008	11,109
Other current assets	7,496	10,063
Total current assets	288,165	425,952
Long-term investments	45,160	0
Property, plant and equipment, net	64,929	65,601
Goodwill	76,501	76,501
Other assets	1,104	817
Total assets	475,859	568,871
Current liabilities:
Accounts payable	6,241	2,816
Accrued compensation	14,346	18,280
Accrued clinical trial expenses	6,683	7,958
Other accrued expenses	6,683	4,711
Interest payable	4,144	4,198
Capital lease obligations, current portion	2,706	2,908
Liability related to refundable upfront payment	12,500	12,500
Deferred revenue, current portion	13,373	14,352
Other current liabilities	5,937	4,499
Total current liabilities	72,613	72,222
Senior secured notes, net	244,336	243,464
Capital lease obligations, less current portion	1,056	2,223
Liability related to the sale of future royalties, net	101,897	105,950
Deferred revenue, less current portion	48,979	51,887
Other long-term liabilities	3,592	5,000
Total liabilities	472,473	480,746
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at June 30, 2017 or December 31, 2016	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 155,861 shares and 153,212 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	15	15
Capital in excess of par value	2,150,019	2,111,483
Accumulated other comprehensive loss	(1,662)	(2,363)
Accumulated deficit	(2,144,986)	(2,021,010)
Total stockholders’ equity	3,386	88,125
Total liabilities and stockholders’ equity	$ 475,859	$ 568,871